blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3313878

EP3313878 - MATERIALS AND METHODS FOR PERFORMING HISTOCHEMICAL ASSAYS FOR HUMAN PRO-EPIREGULIN AND AMPHIREGULIN [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  22.07.2022
Database last updated on 02.11.2024
FormerThe patent has been granted
Status updated on  13.08.2021
FormerGrant of patent is intended
Status updated on  14.03.2021
FormerExamination is in progress
Status updated on  19.10.2020
FormerGrant of patent is intended
Status updated on  04.08.2020
FormerExamination is in progress
Status updated on  02.11.2018
FormerRequest for examination was made
Status updated on  30.03.2018
FormerThe international publication has been made
Status updated on  06.01.2017
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024  [2024/42]
Applicant(s)For all designated states
Ventana Medical Systems, Inc.
1910 E. Innovation Park Drive
Tucson, Arizona 85755 / US
[2021/36]
Former [2018/18]For all designated states
Ventana Medical Systems, Inc.
1910 E. Innovation Park Drive
Tucson, Arizona 85755 / US
For all designated states
Spring Bioscience Corporation
4300 Hacienda Drive
Pleasanton, CA 94588 / US
Inventor(s)01 / SINGH, Shalini
5741 N. Moccasin Trail
Tucson, Arizona 85750 / US
02 / ZHU, Yifei
1408 Maxwell Way
San Jose, California 95131 / US
03 / LIAO, Zhiming
175 Medina Street
Livermore, California 94550 / US
04 / MURANYI, Andrea
6181 N. Camino Padre Isidoro
Tucson, Arizona 85718 / US
05 / SHANMUGAM, Kandavel
1262 East Placita Oro Fino
Oro Valley, AZ 85755 / US
06 / COUTO, Fernando
7814 Oak Creek Drive
Pleasanton, California 94588 / US
 [2021/37]
Former [2018/18]01 / SINGH, Shalini
5741 N. Moccasin Trail
Tucson, Arizona 85750 / US
02 / ZHU, Yifei
1408 Maxwell Way
San Jose, California 95131 / US
03 / LIAO, Zhiming
175 Medina Street
Livermore, California 94550 / US
04 / MURANYI, Andrea
6181 N. Camino Padre Isidoro
Tucson, Arizona 85718 / US
05 / SHANMUGAM, Kandavel
3881 W. Jasper Dr.
Chandler, Arizona 85226 / US
06 / COUTO, Fernando
7814 Oak Creek Drive
Pleasanton, California 94588 / US
Representative(s)Burger, Alexander
Roche Diagnostics GmbH
Patentabteilung
Nonnenwald 2
82377 Penzberg / DE
[2021/37]
Former [2018/18]Burger, Alexander
Roche Diagnostics GmbH Patent Department (LPP.....6164) P.O.Box 11 52
82372 Penzberg / DE
Application number, filing date16733457.227.06.2016
[2018/18]
WO2016EP64883
Priority number, dateUS201562186251P29.06.2015         Original published format: US 201562186251 P
[2018/18]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017001350
Date:05.01.2017
Language:EN
[2017/01]
Type: A1 Application with search report 
No.:EP3313878
Date:02.05.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 05.01.2017 takes the place of the publication of the European patent application.
[2018/18]
Type: B1 Patent specification 
No.:EP3313878
Date:15.09.2021
Language:EN
[2021/37]
Search report(s)International search report - published on:EP05.01.2017
ClassificationIPC:C07K16/22, C07K16/30
[2018/18]
CPC:
G01N33/57496 (EP,US); C07K16/22 (EP,US); C07K16/30 (EP,US);
C07K2317/20 (US); C07K2317/34 (EP,US); C07K2317/92 (EP,US);
G01N2333/485 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/18]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:MATERIALIEN UND VERFAHREN ZUR DURCHFÜHRUNG HISTOCHEMISCHER TESTS FÜR MENSCHLICHES PRO-EPIREGULIN UND AMPHIREGULIN[2018/18]
English:MATERIALS AND METHODS FOR PERFORMING HISTOCHEMICAL ASSAYS FOR HUMAN PRO-EPIREGULIN AND AMPHIREGULIN[2018/18]
French:MATÉRIAUX ET PROCÉDÉS PERMETTANT D'EFFECTUER DES ANALYSES HISTOCHIMIQUES POUR LA PRO-ÉPIRÉGULINE HUMAINE ET L'AMPHIRÉGULINE HUMAINE[2018/18]
Entry into regional phase29.01.2018National basic fee paid 
29.01.2018Designation fee(s) paid 
29.01.2018Examination fee paid 
Examination procedure05.12.2017Amendment by applicant (claims and/or description)
05.12.2017Date on which the examining division has become responsible
29.01.2018Examination requested  [2018/18]
30.10.2018Despatch of a communication from the examining division (Time limit: M04)
25.01.2019Reply to a communication from the examining division
07.06.2019Despatch of a communication from the examining division (Time limit: M06)
04.12.2019Reply to a communication from the examining division
20.03.2020Despatch of a communication from the examining division (Time limit: M04)
14.05.2020Reply to a communication from the examining division
05.08.2020Communication of intention to grant the patent
16.10.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
15.03.2021Communication of intention to grant the patent
20.07.2021Fee for grant paid
20.07.2021Fee for publishing/printing paid
20.07.2021Receipt of the translation of the claim(s)
Divisional application(s)EP19153762.0  / EP3514174
EP21194129.9  / EP3978525
Opposition(s)16.06.2022No opposition filed within time limit [2022/34]
Fees paidRenewal fee
08.06.2018Renewal fee patent year 03
10.06.2019Renewal fee patent year 04
31.03.2020Renewal fee patent year 05
08.06.2021Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU27.06.2016
AL15.09.2021
AT15.09.2021
CY15.09.2021
CZ15.09.2021
DK15.09.2021
EE15.09.2021
FI15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
MC15.09.2021
MK15.09.2021
MT15.09.2021
NL15.09.2021
PL15.09.2021
RO15.09.2021
RS15.09.2021
SE15.09.2021
SI15.09.2021
SK15.09.2021
SM15.09.2021
TR15.09.2021
BG15.12.2021
NO15.12.2021
GR16.12.2021
IS15.01.2022
PT17.01.2022
[2024/42]
Former [2024/29]HU27.06.2016
AL15.09.2021
AT15.09.2021
CY15.09.2021
CZ15.09.2021
DK15.09.2021
EE15.09.2021
FI15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
MC15.09.2021
MK15.09.2021
NL15.09.2021
PL15.09.2021
RO15.09.2021
RS15.09.2021
SE15.09.2021
SI15.09.2021
SK15.09.2021
SM15.09.2021
TR15.09.2021
BG15.12.2021
NO15.12.2021
GR16.12.2021
IS15.01.2022
PT17.01.2022
Former [2024/22]HU27.06.2016
AL15.09.2021
AT15.09.2021
CY15.09.2021
CZ15.09.2021
DK15.09.2021
EE15.09.2021
FI15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
MC15.09.2021
MK15.09.2021
NL15.09.2021
PL15.09.2021
RO15.09.2021
RS15.09.2021
SE15.09.2021
SI15.09.2021
SK15.09.2021
SM15.09.2021
BG15.12.2021
NO15.12.2021
GR16.12.2021
IS15.01.2022
PT17.01.2022
Former [2024/20]HU27.06.2016
AL15.09.2021
AT15.09.2021
CY15.09.2021
CZ15.09.2021
DK15.09.2021
EE15.09.2021
FI15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
MC15.09.2021
NL15.09.2021
PL15.09.2021
RO15.09.2021
RS15.09.2021
SE15.09.2021
SI15.09.2021
SK15.09.2021
SM15.09.2021
BG15.12.2021
NO15.12.2021
GR16.12.2021
IS15.01.2022
PT17.01.2022
Former [2024/18]HU27.06.2016
AL15.09.2021
AT15.09.2021
CZ15.09.2021
DK15.09.2021
EE15.09.2021
FI15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
MC15.09.2021
NL15.09.2021
PL15.09.2021
RO15.09.2021
RS15.09.2021
SE15.09.2021
SI15.09.2021
SK15.09.2021
SM15.09.2021
BG15.12.2021
NO15.12.2021
GR16.12.2021
IS15.01.2022
PT17.01.2022
Former [2023/08]AL15.09.2021
AT15.09.2021
CZ15.09.2021
DK15.09.2021
EE15.09.2021
FI15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
MC15.09.2021
NL15.09.2021
PL15.09.2021
RO15.09.2021
RS15.09.2021
SE15.09.2021
SI15.09.2021
SK15.09.2021
SM15.09.2021
BG15.12.2021
NO15.12.2021
GR16.12.2021
IS15.01.2022
PT17.01.2022
Former [2022/36]AL15.09.2021
AT15.09.2021
CZ15.09.2021
DK15.09.2021
EE15.09.2021
FI15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
NL15.09.2021
PL15.09.2021
RO15.09.2021
RS15.09.2021
SE15.09.2021
SI15.09.2021
SK15.09.2021
SM15.09.2021
BG15.12.2021
NO15.12.2021
GR16.12.2021
IS15.01.2022
PT17.01.2022
Former [2022/29]AL15.09.2021
AT15.09.2021
CZ15.09.2021
EE15.09.2021
FI15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
NL15.09.2021
PL15.09.2021
RO15.09.2021
RS15.09.2021
SE15.09.2021
SK15.09.2021
SM15.09.2021
BG15.12.2021
NO15.12.2021
GR16.12.2021
IS15.01.2022
PT17.01.2022
Former [2022/25]AT15.09.2021
CZ15.09.2021
EE15.09.2021
FI15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
NL15.09.2021
PL15.09.2021
RO15.09.2021
RS15.09.2021
SE15.09.2021
SK15.09.2021
SM15.09.2021
BG15.12.2021
NO15.12.2021
GR16.12.2021
IS15.01.2022
PT17.01.2022
Former [2022/24]AT15.09.2021
CZ15.09.2021
EE15.09.2021
FI15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
NL15.09.2021
PL15.09.2021
RO15.09.2021
RS15.09.2021
SE15.09.2021
SK15.09.2021
BG15.12.2021
NO15.12.2021
GR16.12.2021
IS15.01.2022
PT17.01.2022
Former [2022/23]AT15.09.2021
CZ15.09.2021
EE15.09.2021
FI15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
PL15.09.2021
RS15.09.2021
SE15.09.2021
SK15.09.2021
BG15.12.2021
NO15.12.2021
GR16.12.2021
PT17.01.2022
Former [2022/21]AT15.09.2021
FI15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
RS15.09.2021
SE15.09.2021
BG15.12.2021
NO15.12.2021
GR16.12.2021
Former [2022/10]FI15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
RS15.09.2021
SE15.09.2021
BG15.12.2021
NO15.12.2021
GR16.12.2021
Former [2022/09]FI15.09.2021
LT15.09.2021
RS15.09.2021
SE15.09.2021
BG15.12.2021
NO15.12.2021
Former [2022/08]FI15.09.2021
LT15.09.2021
SE15.09.2021
BG15.12.2021
NO15.12.2021
Former [2022/07]LT15.09.2021
NO15.12.2021
Cited inInternational search[A]WO2008044068  (FUSION ANTIBODIES LTD [GB], et al) [A] 33-72 * page 77, lines 22-26; figures 17-32 *;
 [XI]  - S. A. PRADHAN ET AL, "Evidence that TSC2 acts as a transcription factor and binds to and represses the promoter of Epiregulin", NUCLEIC ACIDS RESEARCH, GB, (20140602), vol. 42, no. 10, doi:10.1093/nar/gku278, ISSN 0305-1048, pages 6243 - 6255, XP055297266 [X] 1,27-32,52-69 * page 6244, column r, line 1; figure 5A * [I] 2-13,70-72

DOI:   http://dx.doi.org/10.1093/nar/gku278
    [ ] - Abcam, "Anti-EREG antibody -C-terminal", (20140206), URL: http://www.abcam.com/EREG-antibody-C-terminal-ab175118.pdf, (20160824), XP055297270 [ ] * the whole document *
 [XI]  - Cell Signaling Technology, "EREG (D4O5I) Rabbit mAb", (20140917), URL: http://media.cellsignal.com/pdf/12048.pdf, (20160823), XP055297126 [X] 1,27-32,52-69 * the whole document * [I] 2-13,70-72
 [I]  - J. ZHANG ET AL, "Intratumoral Epiregulin Is a Marker of Advanced Disease in Non-Small Cell Lung Cancer Patients and Confers Invasive Properties on EGFR-Mutant Cells", CANCER PREVENTION RESEARCH, United States, (20080518), vol. 1, no. 3, doi:10.1158/1940-6207.CAPR-08-0014, ISSN 1940-6207, pages 201 - 207, XP055297042 [I] 1-13,27-32,52-72 * figure 1 *

DOI:   http://dx.doi.org/10.1158/1940-6207.CAPR-08-0014
 [XI]  - AHLBORG N ET AL, "Generation of antibodies to human IL-12 and amphiregulin by immunization of Balb/c mice with diepitope multiple antigen peptides - I. Determination of the selectivity of six antibodies by cell-ELISA and immunofluorescence", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, (19970512), vol. 204, no. 1, doi:10.1016/S0022-1759(97)00035-5, ISSN 0022-1759, pages 23 - 32, XP004107713 [X] 33,46 * figures 1-4; table 1 * [I] 34-45,47-72

DOI:   http://dx.doi.org/10.1016/S0022-1759(97)00035-5
 [XI]  - M. ISOKANE ET AL, "Plasma-membrane-anchored growth factor pro-amphiregulin binds A-type lamin and regulates global transcription", JOURNAL OF CELL SCIENCE, GB, (20081101), vol. 121, no. 21, doi:10.1242/jcs.031443, ISSN 0021-9533, pages 3608 - 3618, XP055306354 [X] 33,46-69 * page 3617, column l, paragraphs 1-3; figures 1-8 * [I] 34-45,70-72

DOI:   http://dx.doi.org/10.1242/jcs.031443
 [A]  - D J JONKER ET AL, "Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer", BRITISH JOURNAL OF CANCER, GB, (20131212), vol. 110, no. 3, doi:10.1038/bjc.2013.753, ISSN 0007-0920, pages 648 - 655, XP055297354 [A] 1-13,27-32,52-72 * figures 1-3; tables 1,2 *

DOI:   http://dx.doi.org/10.1038/bjc.2013.753
 [A]  - FUSANORI YOTSUMOTO ET AL, "Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer", CANCER SCIENCE, JP, (20100707), vol. 101, no. 11, doi:10.1111/j.1349-7006.2010.01671.x, ISSN 1347-9032, pages 2351 - 2360, XP055226799 [A] 33-72 * the whole document *

DOI:   http://dx.doi.org/10.1111/j.1349-7006.2010.01671.x
 [A]  - N. ECKSTEIN ET AL, "Epidermal Growth Factor Receptor Pathway Analysis Identifies Amphiregulin as a Key Factor for Cisplatin Resistance of Human Breast Cancer Cells", JOURNAL OF BIOLOGICAL CHEMISTRY, US, (20080111), vol. 283, no. 2, doi:10.1074/jbc.M706287200, ISSN 0021-9258, pages 739 - 750, XP055280410 [A] 33-72 * the whole document *

DOI:   http://dx.doi.org/10.1074/jbc.M706287200
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.